Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6 results about "Chronic renal insufficiency" patented technology

Renal Insufficiency. a syndrome in which all kidney functions are impaired; it results in disturbance of water, electrolyte, and nitrogen metabolism. Renal insufficiency may be acute or chronic. Acute renal insufficiency may be caused by shock resulting from trauma, burns, blood transfusions, or surgery.

Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound

PendingUS20260070923A1Organic active ingredientsAntipyreticDiseaseChronic renal insufficiency
The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.
Owner:JW PHARMA CORP

ADAMTS12 and HMCN1 as target molecules for the treatment of chronic kidney disease and renal fibrosis

The present invention relates to the interaction of the protein HMCN1 (hemicentin 1 or fibulin 6) as a substrate of the protease ADAMTS12 (a disintegrin and metalloproteinase with thrombospondin motif 12 protein) in the pathogenesis of chronic kidney and heart diseases, and in particular chronic renal insufficiency and renal fibrosis, and heart failure and cardiac fibrosis, respectively. The present invention further relates to methods for identifying compounds that bind to and / or inhibit the protease ADAMTS12, as well as pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active substances that inhibit the cleavage and digestion of hemicentin 1 by the metalloprotease ADAMTS12 or the interaction of hemicentin 1 with ADAMTS12.
Owner:RWTH AACHEN UNIV

Target molecule ADAMTS12 for treating chronic renal insufficiency and renal fibrosis

PendingCN120322676ACompound screeningApoptosis detectionActive agentChronic renal insufficiency
The present invention relates to the use of ADAMTS12 protein, a disintegrin and metalloproteinase 12 protein having a platelet-reactive protein motif, in the development of chronic kidney diseases, in particular progressive chronic kidney diseases and renal fibrosis. In particular, the present invention relates to a method for identifying compounds that bind to ADAMTS12 protein and the use of ADAMTS12 protein for screening and identifying ADAMTS12 interacting compounds and ADAMTS12 inhibiting compounds. The present invention also relates to pharmaceutical compositions for the treatment of kidney diseases, in particular pharmaceutical compositions comprising active agents that bind to and / or inhibit ADAMTS12 protein (Fig. 5).
Owner:RWTH AACHEN UNIV

Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound

ActiveUS12497410B2Organic active ingredientsAntipyreticDiseaseChronic renal insufficiency
The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.
Owner:JW PHARMA CORP

Traditional Chinese medicine composition for tonifying spleen and kidney, medicine and preparation method of traditional Chinese medicine composition

The invention relates to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for tonifying spleen and kidney, a medicine and a preparation method thereof. The traditional Chinese medicine composition aims to solve the problems of treating symptoms but not root causes of chronic renal insufficiency in the prior art, can effectively reduce key indexes (such as creatinine and urea nitrogen) of the renal insufficiency, can start from pathogenesis, has the effects of strengthening spleen and tonifying kidney to consolidate the root, dissolving turbidity and dredging collaterals to treat symptoms, and can avoid adverse reactions caused by long-term medication.
Owner:CHONGQING UNIVERSITY THREE GORGES HOSPITAL

Adamts12 as a target molecule for the treatment of chronic renal insufficiency and renal fibrosis

PendingUS20260202408A1Active agentChronic renal insufficiency
The present invention relates to the role of ADAMTS12 protein (A Disintegrin And Metalloproteinase with ThromboSpondin motifs 12 protein) in the development of chronic kidney disease, in particular progressive chronic kidney disease and renal fibrosis. In particular, the present invention relates to methods for identifying compounds that bind to the ADAMTS12 protein and to the use of ADAMTS12 protein for screening and identifying ADAMTS12-interacting and ADAMTS12-inhibiting compounds. The present invention further relates to pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active agents that bind to and / or inhibit the ADAMTS12 protein.
Owner:RWTH AACHEN UNIV